Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | GPR3 | P46089 | 2/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.36 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22664654 | 0.84 | HTR2A (0.58) | HTR2ACA1CA2GPR3TDO2 | |
| SCHEMBL7576966 | 0.78 | HTR2A (0.64) | HTR2ACA1CA2GPR3TDO2 | |
| SCHEMBL5353138 | 0.78 | HTR2A (0.64) | HTR2ACA1CA2GPR3TDO2 | |
| SCHEMBL7574105 | 0.76 | HTR2A (0.61) | HTR2ACA1CA2GPR3TDO2 | |
| SCHEMBL17022715 | 0.76 | HTR2A (0.61) | HTR2ACA1CA2GPR3TDO2 | |
| SCHEMBL633764 | 0.74 | HTR2A (0.58) | HTR2ACA1CA2GPR3TDO2 | |
| SCHEMBL261028 | 0.74 | HTR2A (0.58) | HTR2ACA1CA2GPR3TDO2 | |
| SCHEMBL2286468 | 0.74 | HTR2A (0.58) | HTR2ACA1CA2GPR3TDO2 | |
| SCHEMBL13715483 | 0.74 | HTR2A (0.58) | HTR2ACA1CA2GPR3TDO2 | |
| SCHEMBL499897 | 0.74 | HTR2A (0.58) | HTR2ACA1CA2GPR3TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108697714-B | Fused pyrimidine compound or salt thereof | 大鹏药品工业株式会社 | 2022-04-26 | — | — | CN | disclosed |
| US-11046696-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-29 | — | — | US | disclosed |
| US-11008324-B2 | — | — | 2021-05-18 | — | — | US | disclosed |
| US-10807986-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-10-20 | — | — | US | disclosed |
| US-20200270253-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-08-27 | — | — | US | disclosed |
| US-20190330214-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-10-31 | — | — | US | disclosed |
| US-10155768-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-12-18 | — | — | US | disclosed |
| EP-3269370-A1 | NOVEL CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2018-01-17 | — | — | EP | disclosed |
| US-20180009818-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-01-11 | — | — | US | disclosed |
| US-20080214754-A1 | DIENE POLYMER AND PROCESS FOR PRODUCING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330214-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, ZFX, PDCD11 | HTR2A 4510/4885CA1 2776/4885CA2 1856/4885 |
| US-20180009818-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, ZFX, PDCD11 | HTR2A 4510/4885CA1 2776/4885CA2 1856/4885 |
| US-11046696-B2 | Fused pyrimidine compound or salt thereof | RET, ZFX, MECP2 | HTR2A 4273/4885CA1 2802/4885CA2 1887/4885 |
| US-11008324-B2 | — | RET, GFRA1, GFRA2 | HTR2A 4175/4885CA1 1154/4885CA2 545/4885 |
| US-10155768-B2 | Fused pyrimidine compound or salt thereof | RET, ZFX, MECP2 | HTR2A 4273/4885CA1 2802/4885CA2 1887/4885 |
| US-10807986-B2 | Fused pyrimidine compound or salt thereof | RET, ZFX, MECP2 | HTR2A 4273/4885CA1 2802/4885CA2 1887/4885 |
| US-20200270253-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, ZFX, PDCD11 | HTR2A 4510/4885CA1 2776/4885CA2 1856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.